… drugs for the treatment of (idiopathic) pulmonary fibrosis have fuelled basic, translational and
clinical research and drug development … and precision medicine in drug development and …

… cells in the initiation of pulmonary fibrosis has been … lung fibrosis, the first model derived
from an IPF-associated gene that has been demonstrated to develop spontaneous lung fibrosis (…

… pulmonary fibrosis. Although the etiology of IPF is unknown, many novel therapeutic targets
and agents have emerged from clinical … AECs are involved in pulmonary fibrosis (Figure 2A). …

… effort from patients, physicians, clinical and basic scientists, and the pharmaceutical
industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of …

… pulmonary fibrosis (IPF) is an area of high unmet clinical … developing these are, in part,
being shaped by existing therapies, and several challenges to drug discovery and development …

… The approval of pirfenidone and nintedanib has fueled IPF drug discovery and development.
New drugs are likely to reach the clinic in the near future. However, numerous challenges …

… of pulmonary fibrosis in mice [Citation24]. One study reported … production and fibrosis
progression in the lung based on the … inhibit pulmonary fibrosis in bleomycin-induced lung fibrosis …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a median survival of 3–5
years (1, 2). The approval of nintedanib and pirfenidone by regulatory agencies worldwide has …

… responsible for progressive fibrotic diseases and use … drug development pipeline for
pulmonary fibrosis. Combination with appropriate preclinical models with ex vivo (precision-cut lung …

… Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease that results in loss …
for IPF drug development, there is an unmet need for clinical trial designs to establish clinical …